Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 4/2011

01-04-2011 | Review Article

Schizoaffective Disorder

A Review of Current Research Themes and Pharmacological Management

Authors: Dr Joshua T. Kantrowitz, Leslie Citrome

Published in: CNS Drugs | Issue 4/2011

Login to get access

Abstract

Despite a clear recognition of the existence of patients with co-morbid psychotic and mood symptoms, many studies conclude that schizoaffective disorder as a distinct diagnosis does not exist. Regardless of one’s opinion on schizoaffective disorder, psychiatrists remain dependent on phenomenological descriptions for diagnosing psychiatric disorders, and these phenomenological criteria are also used for clinical trial entry. On the other hand, many psychiatrists prescribe for specific target symptoms and do not always rigidly follow diagnostic systems and, moreover, there have been very few trials that have specifically studied schizoaffective disorder.
Despite recent intriguing work in epidemiology, genetics, neurocognition and electrophysiology, the diagnosis of schizoaffective disorder remains controversial. Taken together, these studies suggest that even if schizoaffective disorder exists as a separate diagnosis, it may not be useful clinically due to considerable variation in the general use of this term. It is possible that diagnostic criteria in the future will include genetic, imaging and electrophysiological components, and that this will allow for better differentiation of disease states among the heterogeneous pool of patients currently believed to have schizophrenia, schizoaffective disorder or bipolar disorder.
Although it is likely that most, if not all, antipsychotics are effective for schizoaffective disorder, given recent regulatory approval of a specific antipsychotic agent for the acute treatment of schizoaffective disorder, greater attention is now being focused on the entity of schizoaffective disorder and potential treatment decisions. However, based on the limited extant evidence, it is not yet possible to make definitive treatment recommendations for schizoaffective disorder. Additional clinical trials that include other antipsychotics, mood stabilizers and antidepressants are desirable and necessary before clear and comprehensive evidence-based treatment recommendations can be made.
Literature
1.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington,DC: American Psychiatric Association, 2000
2.
Lake CR, Hurwitz N. Schizoaffective disorders are psychotic mood disorders: there are no schizoaffective disorders. Psychiatry Res 2006 Aug 30; 143(2–3): 255–87PubMedCrossRef
3.
Heckers S. Is schizoaffective disorder a useful diagnosis? Curr Psychiatry Rep 2009 Aug; 11(4): 332–7PubMedCrossRef
4.
Abrams DJ, Rojas DC, Arciniegas DB. Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatr Dis Treat 2008 Dec; 4(6): 1089–109PubMedCrossRef
5.
Kraepelin E. Dementia praecox and paraphrenia. Edinburgh: Livingston, 1919
6.
Kasanin J. The acute schizoaffective psychoses. Am J Psychiatry 1933; 90: 97–126
7.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, rev. Washington,DC: American Psychiatric Association, 1987
8.
Spitzer RL, Robins E, Endicott J. Research diagnostic criteria (RDC) for a selected group of functional disorders. 3rd ed. New York: New York State Psychiatric Institute, 1981
9.
World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization, 1993
10.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington,DC: American Psychiatric Association, 1980
11.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington,DC: American Psychiatric Association, 1994
12.
World Health Organization. The ICD-9 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization, 1978
13.
Flaum M, Amador X, Gorman JM. DSM-IV field trial for schizophrenia and other psychotic disorders. In: Widiger TA, Frances AJ, Pincus HA, editors. DSM-IV sourcebook. Washington,DC: American Psychiatric Association, 1994: 687–713
14.
Cheniaux E, Landeira-Fernandez J, Lessa Telles L, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord 2008 Mar; 106(3): 209–17PubMedCrossRef
15.
Vollmer-Larsen A, Jacobsen TB, Hemmingsen R, et al. Schizoaffective disorder: the reliability of its clinical diagnostic use. Acta Psychiatr Scand 2006 May; 113(5): 402–7PubMedCrossRef
16.
Laursen TM, Agerbo E, Pedersen CB. Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index. J Clin Psychiatry 2009 Oct; 70(10): 1432–8PubMedCrossRef
17.
Maj M, Starace F, Kemali D. Prediction of outcome by historical, clinical and biological variables in schizoaffective disorder, depressed type. J Psychiatr Res 1987; 21(3): 289–95PubMedCrossRef
18.
Malhi GS, Green M, Fagiolini A, et al. Schizoaffective disorder: diagnostic issues and future recommendations. Bipolar Disord 2008 Feb; 10 (1 Pt 2): 215–30PubMedCrossRef
19.
Conus P, Abdel-Baki A, Harrigan S, et al. Pre-morbid and outcome correlates of first episode mania with psychosis: is a distinction between schizoaffective and bipolar I disorder valid in the early phase of psychotic disorders? J Affect Disord 2010 Oct; 126(1–2): 88–95PubMedCrossRef
20.
Jager M, Bottlender R, Strauss A, et al. Fifteen-year follow-up of ICD-10 schizoaffective disorders compared with schizophrenia and affective disorders. Acta Psychiatr Scand 2004 Jan; 109(1): 30–7PubMedCrossRef
21.
Bottlender R, Strauss A, Moller HJ. Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission. Schizophr Res 2010 Jan; 116(1): 9–15PubMedCrossRef
22.
Saracco-Alvarez R, Rodriguez-Verdugo S, Garcia-Anaya M, et al. Premorbid adjustment in schizophrenia and schizoaffective disorder. Psychiatry Res 2009 Feb 28; 165(3): 234–40PubMedCrossRef
23.
Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982; 8(3): 470–84PubMedCrossRef
24.
Craddock N, O’Donovan MC, Owen MJ. Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or “schizoaffective”) psychoses. Schizophr Bull 2009 May; 35(3): 482–90PubMedCrossRef
25.
Hamshere ML, Bennett P, Williams N, et al. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p 13. Arch Gen Psychiatry 2005 Oct; 62(10): 1081–8PubMedCrossRef
26.
Chubb JE, Bradshaw NJ, Soares DC, et al. The DISC locus in psychiatric illness. Mol Psychiatry 2008 Jan; 13(1): 36–64PubMedCrossRef
27.
Lindsay EA, Morris MA, Gos A, et al. Schizophrenia and chromosomal deletions within 22q 11. 2. Am J Hum Genet 1995 Jun; 56(6): 1502–3
28.
Nabi MO, Mirabzadeh A, Feizzadeh G, et al. Novel mutations in the calreticulin gene core promoter and coding sequence in schizoaffective disorder. Am J Med Genet B Neuropsychiatr Genet 2010 Mar 5; 153B(2): 706–9PubMed
29.
Nunes A, Ohadi M, Rahimi A, et al. A mutation in the calreticulin gene promoter in a family case of schizoaffective disorder leads to its aberrant transcriptional activation. Brain Res 2008 Nov 6; 1239: 36–41PubMedCrossRef
30.
Hamshere ML, Schulze TG, Schumacher J, et al. Mood-incongruent psychosis in bipolar disorder: conditional linkage analysis shows genome-wide suggestive linkage at 1q32.3, 7p13 and 20q13. 31. Bipolar Disord 2009 Sep; 11(6): 610–20CrossRef
31.
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007 Jun 7; 447(7145): 661–78CrossRef
32.
Craddock N, Jones L, Jones IR, et al. Strong genetic evidence for a selective influence of GABAA receptors on a component of the bipolar disorder phenotype [published erratum appears in Mol Psychiatry 2010 Nov; 15 (11): 1121]. Mol Psychiatry 2010 Feb; 15(2): 146–53PubMedCrossRef
33.
Lencz T, Lipsky RH, DeRosse P, et al. Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry 2009 Apr; 194(4): 313–8PubMedCrossRef
34.
Fiszdon JM, Choi J, Goulet J, et al. Temporal relationship between change in cognition and change in functioning in schizophrenia. Schizophr Res 2008; 105(1–3): 105–13PubMedCrossRef
35.
Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 2000; 26(1): 119–36PubMedCrossRef
36.
Buchanan RW, Freedman R, Javitt DC, et al. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007 Sep; 33(5): 1120–30PubMedCrossRef
37.
Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008 Feb; 165(2): 203–13PubMedCrossRef
38.
Walker E. Attentional and neuromotor functions of schizophrenics, schizoaffectives, and patients with other affective disorders. Arch Gen Psychiatry 1981 Dec; 38(12): 1355–8PubMedCrossRef
39.
Maj M. Neuropsychological functioning in schizoaffective disorder, depressed type. Acta Psychiatr Scand 1986 Nov; 74(5): 524–8PubMedCrossRef
40.
Bornstein RA, Nasrallah HA, Olson SC, et al. Neuropsychological deficit in schizophrenic subtypes: paranoid, nonparanoid, and schizoaffective subgroups. Psychiatry Res 1990 Jan; 31(1): 15–24PubMedCrossRef
41.
Beatty WW, Jocic Z, Monson N, et al. Memory and frontal lobe dysfunction in schizophrenia and schizoaffective disorder. J Nerv Ment Dis 1993 Jul; 181(7): 448–53PubMedCrossRef
42.
Stip E, Sepehry AA, Prouteau A, et al. Cognitive discernible factors between schizophrenia and schizoaffective disorder. Brain Cogn 2005 Dec; 59(3): 292–5PubMedCrossRef
43.
Goldstein G, Shemansky WJ, Allen DN. Cognitive function in schizoaffective disorder and clinical subtypes of schizophrenia. Arch Clin Neuropsychol 2005 Mar; 20(2): 153–9PubMedCrossRef
44.
Gruber O, Gruber E, Falkai P. Articulatory rehearsal in verbal working memory: a possible neurocognitive endophenotype that differentiates between schizophrenia and schizoaffective disorder. Neurosci Lett 2006 Sep 11; 405(1–2): 24–8PubMedCrossRef
45.
Evans JD, Heaton RK, Paulsen JS, et al. Schizoaffective disorder: a form of schizophrenia or affective disorder? J Clin Psychiatry 1999 Dec; 60(12): 874–82PubMedCrossRef
46.
Miller LS, Swanson-Green T, Moses Jr JA, et al. Comparison of cognitive performance in RDC-diagnosed schizoaffective and schizophrenic patients with the Luria-Nebraska Neuropsychological Battery. J Psychiatr Res 1996 Jul–Aug; 30(4): 277–82PubMedCrossRef
47.
Reichenberg A, Weiser M, Rabinowitz J, et al. A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am J Psychiatry 2002 Dec; 159(12): 2027–35PubMedCrossRef
48.
Townsend LA, Malla AK, Norman RM. Cognitive functioning in stabilized first-episode psychosis patients. Psychiatry Res 2001 Nov 1; 104(2): 119–31PubMedCrossRef
49.
Fiszdon JM, Richardson R, Greig T, et al. A comparison of basic and social cognition between schizophrenia and schizoaffective disorder. Schizophr Res 2007 Mar; 91(1–3): 117–21PubMedCrossRef
50.
Heinrichs RW, Ammari N, McDermid Vaz S, et al. Are schizophrenia and schizoaffective disorder neuropsychologically distinguishable? Schizophr Res 2008 Feb; 99(1–3): 149–54PubMedCrossRef
51.
Hooper SR, Giuliano AJ, Youngstrom EA, et al. Neurocognition in early-onset schizophrenia and schizoaffective disorders. J Am Acad Child Adolesc Psychiatry 2010 Jan; 49(1): 52–60PubMed
52.
Krabbendam L, Arts B, van Os J, et al. Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr Res 2005 Dec 15; 80(2–3): 137–49PubMedCrossRef
53.
Hill SK, Harris MS, Herbener ES, et al. Neurocognitive allied phenotypes for schizophrenia and bipolar disorder. Schizophr Bull 2008 Jul; 34(4): 743–59PubMedCrossRef
54.
Bora E, Yucel M, Pantelis C. Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: metaanalytic study. Br J Psychiatry 2009 Dec; 195(6): 475–82PubMedCrossRef
55.
Bellack AS, Morrison RL, Mueser KT, et al. Social competence in schizoaffective disorder, bipolar disorder, and negative and non-negative schizophrenia. Schizophr Res 1989 Jul–Oct; 2(4–5): 391–401PubMedCrossRef
56.
Torrent C, Martinez-Aran A, Amann B, et al. Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic bipolar and healthy subjects. Acta Psychiatr Scand 2007 Dec; 116(6): 453–60PubMedCrossRef
57.
Szoke A, Meary A, Trandafir A, et al. Executive deficits in psychotic and bipolar disorders: implications for our understanding of schizoaffective disorder. Eur Psychiatry 2008 Jan; 23(1): 20–5PubMedCrossRef
58.
Studentkowski G, Scheele D, Calabrese P, et al. Cognitive impairment in patients with a schizoaffective disorder: a comparison with bipolar patients in euthymia. Eur J Med Res 2010 Feb 26; 15(2): 70–8PubMed
59.
Javitt DC, Spencer KM, Thaker GK, et al. Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 2008; 7(1): 68–83PubMedCrossRef
60.
Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 2005; 76(1): 1–23PubMedCrossRef
61.
Jeon Y, Polich J. P300 asymmetry in schizophrenia: a metaanalysis. Psychiatry Res 2001 Oct 10; 104(1): 61–74PubMedCrossRef
62.
Thaker GK. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr Bull 2008 Jul; 34(4): 760–73PubMedCrossRef
63.
Schellenberg R, Knorr W, Schindler M, et al. EEG-power spectral components of schizoaffective disorders. Schizophr Res 1990 Oct–Dec; 3(5–6): 357–9PubMedCrossRef
64.
Martin LF, Hall MH, Ross RG, et al. Physiology of schizophrenia, bipolar disorder, and schizoaffective disorder. Am J Psychiatry 2007 Dec; 164(12): 1900–6PubMedCrossRef
65.
Reite M, Teale P, Collins D, et al. Schizoaffective disorder: a possible MEG auditory evoked field biomarker. Psychiatry Res 2010 Jun 30; 182(3): 284–6PubMedCrossRef
66.
Spencer KM, Nestor PG, Perlmutter R, et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci U S A 2004 Dec 7; 101(49): 17288–93PubMedCrossRef
67.
Mathalon DH, Hoffman RE, Watson TD, et al. Neurophysiological distinction between schizophrenia and schizoaffective disorder. Front Hum Neurosci 2010; 3: 70PubMed
68.
Mitchell AJ, Malone D. Physical health and schizophrenia. Curr Opin Psychiatry 2006 Jul; 19(4): 432–7PubMedCrossRef
69.
Leucht S, Burkard T, Henderson J, et al. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007 Nov; 116(5): 317–33PubMedCrossRef
70.
Kilbourne AM, Brar JS, Drayer RA, et al. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics 2007 Sep–Oct; 48(5): 412–7PubMedCrossRef
71.
Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70(1): 19–26PubMedCrossRef
72.
Barak Y, Achiron A, Mandel M, et al. Reduced cancer incidence among patients with schizophrenia. Cancer 2005 Dec 15; 104(12): 2817–21PubMedCrossRef
73.
Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med 2006 Sep–Oct; 68(5): 684–91PubMedCrossRef
74.
Levav I, Kohn R, Barchana M, et al. The risk for cancer among patients with schizoaffective disorders. J Affect Disord 2009 Apr; 114(1–3): 316–20PubMedCrossRef
75.
Jäger M, Becker T, Weinmann S, et al. Treatment of schizoaffective disorder: a challenge for evidence-based psychiatry. Acta Psychiatr Scand 2010 Jun 30; 121(1): 22–32PubMedCrossRef
76.
77.
78.
Tohen M, Zhang F, Keck PE, et al. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. J Affect Disord 2001 Dec; 67(1–3): 133–40PubMedCrossRef
79.
Keck Jr PE, Reeves KR, Harrigan EP. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001 Feb; 21(1): 27–35PubMedCrossRef
80.
Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998 Mar; 55(3): 250–8PubMedCrossRef
81.
Tran PV, Tollefson GD, Sanger TM, et al. Olanzapine versus haloperidol in the treatment of schizoaffective disorder: acute and long-term therapy. Br J Psychiatry 1999 Jan; 174: 15–22PubMedCrossRef
82.
Janicak PG, Keck Jr PE, Davis JM, et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol 2001 Aug; 21(4): 360–8PubMedCrossRef
83.
Mattes JA, Nayak D. Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. Biol Psychiatry 1984 Mar; 19(3): 445–9PubMed
84.
Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomised study. J Affect Disord 1997 Apr; 43(2): 151–61PubMedCrossRef
85.
Glick ID, Mankoski R, Eudicone JM, et al. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord 2009 May; 115(1–2): 18–26PubMedCrossRef
86.
Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002 Sep; 63(9): 763–71PubMedCrossRef
87.
Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an anti-psychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003 Jul; 60(7): 681–90PubMedCrossRef
88.
Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evidence 2008; 2(4): 261–71PubMed
89.
Nussbaum AM, Stroup TS. Paliperidone for treatment of schizophrenia. Schizophr Bull 2008 May; 34(3): 419–22PubMedCrossRef
90.
91.
92.
Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 2010 May; 71(5): 587–98PubMedCrossRef
93.
Canuso CM, Schooler N, Carothers J, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol 2010 Oct; 30(5): 487–95PubMedCrossRef
94.
Biederman J, Lerner Y, Belmaker RH. Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study. Arch Gen Psychiatry 1979 Mar; 36(3): 327–33PubMedCrossRef
95.
Carman JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 1981 Mar; 42(3): 124–8PubMed
96.
Muller-Siecheneder F, Muller MJ, Hillert A, et al. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998 Apr; 18(2): 111–20PubMedCrossRef
97.
Roy Chengappa K, Kupfer DJ, Parepally H, et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord 2007 Sep; 9(6): 609–17PubMedCrossRef
Metadata
Title
Schizoaffective Disorder
A Review of Current Research Themes and Pharmacological Management
Authors
Dr Joshua T. Kantrowitz
Leslie Citrome
Publication date
01-04-2011
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 4/2011
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/11587630-000000000-00000

Other articles of this Issue 4/2011

CNS Drugs 4/2011 Go to the issue

Review Article

The Role of Antipsychotics in Smoking and Smoking Cessation

Leading Article

Role of Corticotropin-Releasing Factor in Drug Addiction

Review Article

Optimal Frequency of Lithium Administration in the Treatment of Bipolar Disorder

Adis Drug Evaluation

Indomethacin/Prochlorperazine/Caffeine

Adis Drug Profile

Methylphenidate Transdermal System